Anti-Cancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogs

249 Text: 4541 Number of references: 42 Number of figures: 6 Journal Category: Research Article

[1]  N. Vargesson.  Thalidomide‐induced teratogenesis: History and mechanisms , 2015, Birth defects research. Part C, Embryo today : reviews.

[2]  A. Aplin,et al.  The rat aortic ring model of angiogenesis. , 2015, Methods in molecular biology.

[3]  N. Vargesson.  Thalidomide Embryopathy: An Enigmatic Challenge , 2013 .

[4]  Neil Vargesson,et al.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro , 2013, Proceedings of the National Academy of Sciences.

[5]  N. Greig,et al.  Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF-α and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of Inflammation , 2011, The open biochemistry journal.

[6]  S. Lentzsch,et al.  Recent advances of IMiDs in cancer therapy , 2010, Current opinion in oncology.

[7]  James H Doroshow,et al.  Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines , 2010, Molecular Cancer Therapeutics.

[8]  C. Mummery,et al.  Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia , 2010, Nature Medicine.

[9]  M. Smyth,et al.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma , 2010, Leukemia.

[10]  P. L. Bergsagel,et al.  Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Verma,et al.  Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.

[12]  Neil Vargesson,et al.  Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation , 2009, Proceedings of the National Academy of Sciences.

[13]  J. Shaughnessy,et al.  Thalidomide induces limb deformities by perturbing the Bmp/Dkkl/Wnt signaling pathway , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  P. Ingham,et al.  A transgenic zebrafish model of neutrophilic inflammation. , 2006, Blood.

[15]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[16]  M. Indhumathy,et al.  Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells , 2006, BMC Cell Biology.

[17]  S. Srinivas,et al.  A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma , 2005, BJU international.

[18]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Macpherson,et al.  Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice , 2004, Clinical Cancer Research.

[20]  M. Gütschow,et al.  Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. , 2004, Journal of medicinal chemistry.

[21]  L. Mileshkin,et al.  Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. , 2003, Blood.

[22]  M. Gütschow,et al.  Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. , 2003, Cancer research.

[23]  E. Maher,et al.  Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. C. Okafor.  Thalidomide for Erythema Nodosum Leprosum and Other Applications , 2003, Pharmacotherapy.

[25]  Santhosh K. P. Kumar,et al.  Thalidomide as initial therapy for early-stage myeloma , 2003, Leukemia.

[26]  R. Fonseca,et al.  Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. , 2003, Mayo Clinic proceedings.

[27]  H. Goldschmidt,et al.  Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  H. Goldschmidt,et al.  Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. , 2002, Blood.

[29]  B. Weinstein,et al.  In vivo imaging of embryonic vascular development using transgenic zebrafish. , 2002, Developmental biology.

[30]  W. Figg,et al.  5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis , 2002, Therapeutic drug monitoring.

[31]  W. Berdel,et al.  Efficacy and safety of thalidomide in patients with acute myeloid leukemia. , 2002, Blood.

[32]  J Shaughnessy,et al.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.

[33]  S. Steinberg,et al.  A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  S. Steinberg,et al.  Activity of thalidomide in AIDS-related Kaposi's sarcoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Grosbois,et al.  Thalidomide in patients with advanced multiple myeloma. , 2000, The hematology journal : the official journal of the European Haematology Association.

[36]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[37]  Gilla Kaplan,et al.  Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production , 1999 .

[38]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Viktor Hamburger,et al.  A series of normal stages in the development of the chick embryo , 1992, Journal of morphology.